RxDoctor Payments Data

Gregory Fignole

Primary Care · Miami, FLNPI 1104221027

Payments from drug & device makers

$1,044in general payments, 2019–2025

Across 45 payments — averaging $23.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$365
  • Exact Sciences$157
  • Merck$126
  • GSK$113
  • Abbott$83
  • Lilly USA, LLC$61
  • plus $138 from 5 others

What the payments were for

  • Food & beverage$1,044100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,044 in reported general payments places this provider in the 70th percentile of 725 primary care providers in Florida.

See all primary care providers in Florida

Medicare billing

Part B allowed, 2024
$938
Medicare patients
34
Services billed
105

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TivicayDolutegravir Sodium16$50,337
PrezcobixDarunavir/Cobicistat14$37,677
JanuviaSitagliptin Phosphate20$20,204
FarxigaDapagliflozin Propanediol23$17,936
JardianceEmpagliflozin14$16,144
EliquisApixaban19$13,199
Humalog Kwikpen U-100Insulin Lispro15$3,947
Nifedipine ErNifedipine54$693
Gabapentin35$595
Atorvastatin Calcium90$458
Chlorthalidone22$422
Losartan Potassium79$394
Amlodipine Besylate75$319
Metoprolol Succinate27$295
Albuterol Sulfate HfaAlbuterol Sulfate13$285

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Viiv Healthcare CompanyTivicay$34$50,33716 claims
MerckJanuvia$126$20,20420 claims
AstraZenecaFarxiga$365$17,93623 claims
PfizerEliquis$49$13,19919 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 725 primary care providers in Florida.

Other primary care in Miami

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →